AU2013206215C1 - Positively charged water-soluble prodrugs of aspirin - Google Patents
Positively charged water-soluble prodrugs of aspirin Download PDFInfo
- Publication number
- AU2013206215C1 AU2013206215C1 AU2013206215A AU2013206215A AU2013206215C1 AU 2013206215 C1 AU2013206215 C1 AU 2013206215C1 AU 2013206215 A AU2013206215 A AU 2013206215A AU 2013206215 A AU2013206215 A AU 2013206215A AU 2013206215 C1 AU2013206215 C1 AU 2013206215C1
- Authority
- AU
- Australia
- Prior art keywords
- acetylsalicylate
- diethylaminoethyl
- aspirin
- acetylsalicylamide
- dimethylaminoethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 107
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims abstract description 93
- 239000000651 prodrug Substances 0.000 title abstract description 53
- 229940002612 prodrug Drugs 0.000 title abstract description 53
- GHIVDTCFLFLOBV-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-acetyloxybenzoate Chemical compound CCN(CC)CCOC(=O)C1=CC=CC=C1OC(C)=O GHIVDTCFLFLOBV-UHFFFAOYSA-N 0.000 claims abstract description 40
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 25
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 241001465754 Metazoa Species 0.000 claims abstract description 9
- 208000025865 Ulcer Diseases 0.000 claims abstract description 8
- 230000036765 blood level Effects 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- KGHXFBVYXDFJGG-UHFFFAOYSA-N (2-carbamoylphenyl) acetate Chemical compound CC(=O)OC1=CC=CC=C1C(N)=O KGHXFBVYXDFJGG-UHFFFAOYSA-N 0.000 claims description 14
- 150000002500 ions Chemical class 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 229960001860 salicylate Drugs 0.000 claims description 13
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 13
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 230000036470 plasma concentration Effects 0.000 claims description 11
- 208000002193 Pain Diseases 0.000 claims description 9
- 230000036407 pain Effects 0.000 claims description 9
- SWNNLZURDOQIQO-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-acetyloxybenzoate Chemical compound CN(C)CCOC(=O)C1=CC=CC=C1OC(C)=O SWNNLZURDOQIQO-UHFFFAOYSA-N 0.000 claims description 8
- HZELIJJCRIPUGZ-UHFFFAOYSA-N 2-(dipropylamino)ethyl 2-acetyloxybenzoate Chemical compound CCCN(CCC)CCOC(=O)C1=CC=CC=C1OC(C)=O HZELIJJCRIPUGZ-UHFFFAOYSA-N 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- CMQAAPRKYZAPHQ-UHFFFAOYSA-N [2-[2-(diethylamino)ethylsulfanylcarbonyl]phenyl] propanoate Chemical compound CCN(CC)CCSC(=O)C1=CC=CC=C1OC(=O)CC CMQAAPRKYZAPHQ-UHFFFAOYSA-N 0.000 claims description 7
- YIVKJLGSZZHKDG-UHFFFAOYSA-N [2-[2-(dimethylamino)ethylsulfanylcarbonyl]phenyl] acetate Chemical compound CN(C)CCSC(=O)C1=CC=CC=C1OC(C)=O YIVKJLGSZZHKDG-UHFFFAOYSA-N 0.000 claims description 7
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 6
- 229940068372 acetyl salicylate Drugs 0.000 claims description 6
- 206010000496 acne Diseases 0.000 claims description 6
- 229940001468 citrate Drugs 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 206010002388 Angina unstable Diseases 0.000 claims description 4
- 200000000007 Arterial disease Diseases 0.000 claims description 4
- 208000002177 Cataract Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 208000005189 Embolism Diseases 0.000 claims description 4
- 208000005577 Gastroenteritis Diseases 0.000 claims description 4
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 claims description 4
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims description 4
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 206010059054 Shunt thrombosis Diseases 0.000 claims description 4
- 208000001435 Thromboembolism Diseases 0.000 claims description 4
- 208000007814 Unstable Angina Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 206010061592 cardiac fibrillation Diseases 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- 238000007887 coronary angioplasty Methods 0.000 claims description 4
- 230000006866 deterioration Effects 0.000 claims description 4
- 230000003073 embolic effect Effects 0.000 claims description 4
- 208000028208 end stage renal disease Diseases 0.000 claims description 4
- 201000000523 end stage renal failure Diseases 0.000 claims description 4
- 230000002600 fibrillogenic effect Effects 0.000 claims description 4
- 238000001631 haemodialysis Methods 0.000 claims description 4
- 210000003709 heart valve Anatomy 0.000 claims description 4
- 230000000322 hemodialysis Effects 0.000 claims description 4
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 4
- 230000003907 kidney function Effects 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 201000001474 proteinuria Diseases 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 230000036262 stenosis Effects 0.000 claims description 4
- 208000037804 stenosis Diseases 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 230000009424 thromboembolic effect Effects 0.000 claims description 4
- 231100000397 ulcer Toxicity 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 3
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 201000011529 cardiovascular cancer Diseases 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- MLYOZQJITPVSLQ-UHFFFAOYSA-N C(C)(=O)OC=1C(C(=O)NCCN(CC)CC)=CC=CC1 Chemical compound C(C)(=O)OC=1C(C(=O)NCCN(CC)CC)=CC=CC1 MLYOZQJITPVSLQ-UHFFFAOYSA-N 0.000 claims 3
- RUUCMFQDVFDEEB-UHFFFAOYSA-N C(C)(=O)SC=1C(C(=O)OCCN(CC)CC)=CC=CC1 Chemical compound C(C)(=O)SC=1C(C(=O)OCCN(CC)CC)=CC=CC1 RUUCMFQDVFDEEB-UHFFFAOYSA-N 0.000 claims 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 3
- LWPAZXFIWVEABF-UHFFFAOYSA-N [2-[3-(diethylamino)propylcarbamoyl]phenyl] acetate Chemical compound CCN(CC)CCCNC(=O)C1=CC=CC=C1OC(C)=O LWPAZXFIWVEABF-UHFFFAOYSA-N 0.000 claims 3
- 229940039748 oxalate Drugs 0.000 claims 3
- 206010019233 Headaches Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 201000011461 pre-eclampsia Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 208000004371 toothache Diseases 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract description 111
- 229940079593 drug Drugs 0.000 abstract description 19
- 239000012528 membrane Substances 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 14
- 230000002496 gastric effect Effects 0.000 abstract description 10
- UYDSGXAKLVZWIJ-UHFFFAOYSA-N ethyl 2-acetyloxybenzoate Chemical compound CCOC(=O)C1=CC=CC=C1OC(C)=O UYDSGXAKLVZWIJ-UHFFFAOYSA-N 0.000 abstract description 9
- 206010053768 Gastroduodenal haemorrhage Diseases 0.000 abstract description 6
- 239000002253 acid Substances 0.000 abstract description 6
- 125000003277 amino group Chemical group 0.000 abstract description 6
- 241000282412 Homo Species 0.000 abstract description 5
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- 201000006549 dyspepsia Diseases 0.000 abstract description 5
- 208000007882 Gastritis Diseases 0.000 abstract description 4
- 210000000172 cytosol Anatomy 0.000 abstract description 4
- 230000036269 ulceration Effects 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract description 3
- 150000008064 anhydrides Chemical class 0.000 abstract description 2
- 150000004820 halides Chemical class 0.000 abstract description 2
- 150000001298 alcohols Chemical class 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 150000003573 thiols Chemical class 0.000 abstract 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 26
- 239000000203 mixture Substances 0.000 description 23
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 16
- 238000001914 filtration Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 125000003342 alkenyl group Chemical group 0.000 description 11
- 125000003545 alkoxy group Chemical group 0.000 description 11
- 125000003118 aryl group Chemical group 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 230000035515 penetration Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 230000000202 analgesic effect Effects 0.000 description 9
- 230000001754 anti-pyretic effect Effects 0.000 description 9
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 9
- 229960004889 salicylic acid Drugs 0.000 description 9
- QXNKAUNWERFBBV-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-hydroxybenzoate Chemical compound CCN(CC)CCOC(=O)C1=CC=CC=C1O QXNKAUNWERFBBV-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- -1 methyl- Chemical group 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 229940086542 triethylamine Drugs 0.000 description 6
- 230000005779 cell damage Effects 0.000 description 5
- 208000037887 cell injury Diseases 0.000 description 5
- 210000004051 gastric juice Anatomy 0.000 description 5
- 150000003902 salicylic acid esters Chemical class 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000002221 antipyretic Substances 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000012265 solid product Substances 0.000 description 4
- DSGKWFGEUBCEIE-UHFFFAOYSA-N (2-carbonochloridoylphenyl) acetate Chemical compound CC(=O)OC1=CC=CC=C1C(Cl)=O DSGKWFGEUBCEIE-UHFFFAOYSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000008384 membrane barrier Effects 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 206010004053 Bacterial toxaemia Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010070538 Gestational hypertension Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 201000005624 HELLP Syndrome Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 208000013222 Toxemia Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000003356 anti-rheumatic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000013172 carotid endarterectomy Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 230000003931 cognitive performance Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- FGCAKJQRXQLMEA-UHFFFAOYSA-N n-(2-bromoethyl)-n-propylpropan-1-amine Chemical compound CCCN(CCC)CCBr FGCAKJQRXQLMEA-UHFFFAOYSA-N 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 238000002638 palliative care Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 150000003512 tertiary amines Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- UNOPUGNFTOQUIZ-VTSYCQLTSA-N (8s,9s,10r,13s,14s,17s)-17-[4-(dimethylamino)butanoyl]-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)CCCN(C)C)[C@@]1(C)CC2 UNOPUGNFTOQUIZ-VTSYCQLTSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- DENMGZODXQRYAR-UHFFFAOYSA-N 2-(dimethylamino)ethanethiol Chemical compound CN(C)CCS DENMGZODXQRYAR-UHFFFAOYSA-N 0.000 description 1
- WRYDGMWSKBGVHS-UHFFFAOYSA-N 2-bromo-n,n-diethylethanamine Chemical compound CCN(CC)CCBr WRYDGMWSKBGVHS-UHFFFAOYSA-N 0.000 description 1
- XQFQYOHHVAEHPL-UHFFFAOYSA-N 3-(diethylamino)propane-1-thiol Chemical compound CCN(CC)CCCS XQFQYOHHVAEHPL-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- FTKJKXRSODPSDE-UHFFFAOYSA-N benzyl 2-acetyloxybenzoate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 FTKJKXRSODPSDE-UHFFFAOYSA-N 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- WMLQRTQFMFULOA-UHFFFAOYSA-N prop-2-enyl 2-acetyloxybenzoate Chemical group CC(=O)OC1=CC=CC=C1C(=O)OCC=C WMLQRTQFMFULOA-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- JZLOKWGVGHYBKD-UHFFFAOYSA-M sodium;2-acetyloxybenzoate Chemical compound [Na+].CC(=O)OC1=CC=CC=C1C([O-])=O JZLOKWGVGHYBKD-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF Abstract The novel positively charged prodrugs of acetylsalicylic acid and its analogues in the general formula (1) "Structure 1" were designed and synthesized. The compounds of the general formula (1) "Structure 1" indicated above can be prepared from functional derivatives of ASA or its analogues, (for example acid halides or mixed anhydrides), by reaction with suitable alcohols, thiols, or amines. The positively charged amino groups of these pro-drugs not only largely increases the solubility of the drugs, but also bonds to the negative charge on the phosphate head group of membranes and push the pro-drug into the cytosol. The experiment results suggest that the pro-drug, diethylaminoethyl acetylsalicylate.AcOH, diffuses through human skin ~400 times faster than acetylsalicylic acid itself and ~100 times faster than ethyl acetylsalicylate. In plasma, 80% of these pro-drugs can change back to the drug in a few minutes. The pro-drugs can be used medicinally in treating any aspirin-treatable conditions in humans or animals and be administered not only orally, but also transdermally for any kind of medical treatments and avoid most of the side effects of aspirin, most notably GI disturbances such as dyspepsia, gastroduodenal bleeding, gastric ulcerations, and gastritis. Controlled transdermal administration systems of the prodrug enables the aspirin to reach constantly optimal therapeutic blood levels to increase effectiveness and reduce the side effects of aspirin.
Description
Description
POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF
ASPIRIN
Technical Field L] The present invention relates to the preparations of positively charged and water- soluble pro-drugs of aspirin or its analogues and their medicinal use in treating any aspirin-treatable conditions in humans or animals. Particularly, the present invention is to overcome the side effects that are associated with the use of salicylates. These pro-drugs can be administered orally or transdermally.
Background Art i] Acetylsalicylic acid (aspirin) was synthesized in 1853 and first used medicinally in 1899. Since then, numerous derivatives of salicylic acid have been synthesized and evaluated pharmacologically, yet relatively few derivatives have achieved therapeutic utility. Aspirin possesses antipyretic, analgesic, and anti-inflammatory properties. Because salicylates promote the excretion of uric acid, they are useful in the treatment of gouty arthritis. Aspirin also inhibits the platelet aggregation that potentially contributes to heart attacks and stroke [C. H. Hennekens, et al., N. Engl. J. Med., 321, 129(1989); T.A.Gossel, U.S. Pharmacist, February, 1988, p. 34.] and it may be protective against colon cancer as also [MJ.Thun, et al., N. Engl. J. Med., 325, 1393(1991)]. Thus, the therapeutic utility of aspirin is valuable and continues to increase. "PDR Generics" (PDR Generics, 1996, second edition, Medical Economics, Montvale, New Jersey, pg 243) has listed many medical uses of aspirin. Aspirin is also used in the long-term palliative treatment of mild to moderate pain and inflammation of arthritic and other inflammatory conditions. It is used alone or as an adjunct in the treatment of Kawasaki syndrome, thromboembolism after surgery, and unstable angina. It is also used to decrease stool volume and increase weight in acute childhood gastroenteritis, as an adjunct in preventing aortocoronary-artery-bypass graft occlusion, and used to prevent thromboembolic complications in chronic arterial fibrillation. It is used as an adjunct in carotid endarterectomy to reduce platelet aggregatioartrial n, prescribed to reduce the development of cataracts, used to prevent the recurrence of stenosis after coronary angioplasty, and used to improve cognitive performance and cerebral blood flow in patients with multi-infract dementia. It is used as an adjunct to lower plasma glucose in diabetes mellitus and diabetes-induced complications, including diabetic retinopathy, necrobiotic ulcers, and diabetic proteinuria, and to decrease total and cardiovascular mortality. It is prescribed to reduce the incidence of hemodialysis shunt thrombosis, to decrease the deterioration of renal function and the occurrence of end-stage renal disease in patients with type-1 membranoproliferative glomerulonephritis, and to slow progression of peripheral occlussive arterial disease. It is used in the prevention of colon cancer, rectal cancer, and arterial embolic complications in patients' prosthetic heart valves. It is also prescribed to lower the incidence of pregnancy-induced hypertension and preeclamptic toxemia in high-risk women.
Unfortunately, a number of side effects are associated with the use of salicylates, most notably GI disturbances such as dyspepsia, gastroduodenal bleeding, gastric ulcerations, and gastritis. Despite the vast effort expended in the search to find a "better" aspirin, a superior product has yet to be discovered. Aspirin has very low solubility in water and may stay in the GI tract for a long time, thus causing gastric mucosal cell damage. Stable salts of O-acetylsalicylic with base amino acids were studied for their use as medicaments ( Franckowiak, et al., U.S. Pat. No. 6,773,724 ), but as the pH of gastric juice is 1-3, the salts may be acidified to acetylsalicylic acid. Esters of alkyl- or aralkyl-substituted acetylsalicylic acid such as methyl-, ethyl, allyl-, or benzyl acetyl-salicylate were synthesized and studied (Boghosian, et al., U.S. Pat. No. 4,244,948). Higher fatty acid derivatives of salicylic acid and salts thereof were synthesized for use in treating aspirin-treatable conditions (Guttag, U.S. Pat. No. 5,760,261). Esters of salsalate with guaiacol were synthesized and evaluated pharmacologically (Nicolini, U.S. Pat. No. 4,743,704).
Transdermal administration of aspirin has many advantages (Kissel, U.S. Pat. No.5,861,170). 1. Aspirin is directly introduced into the systemic circulation in its pharmacologically active form, thus avoiding metabolism in the gastrointestinal tract; 2. reduction of gastrointestinal side effects; 3. constant therapeutic effect with reduced doses of aspirin; 4. reduced risk of overdosage; 5. treatment of outpatients without the need for observation; and 6. improved patient compliance rate. Attempts have already be made to apply aspirin or its analogues to skin. Burton (Burton, U.S. Pat. No.4,012,508) employed aspirin in combination with corticosteroids for topical application in the case of dermatological indications. Sibalis (Sibalis, U.S. Pat. No.4,640,689) described that there is an increase in the penetration rate of aspirin by employing an electric current. It is very difficult, however, to deliver therapeutically effective plasma levels of aspirin into the host by these methods. Susan Milosovich, et. al. designed and prepared testosteronyl-4-dimethylaminobutyrate.HCl (TSBH), which has a lipophilic portion and a tertiary amine groups that exists in the protonated form at physiologic pH. They found that the pro-drug (TSBH) diffuses through human skin ~60 times faster than does the drug (TS) itself [Susan Milosovich, et al., J. Pharm. Sci., 82, 227(1993)].
Disclosure of Invention
Technical Problem
Aspirin is a very old salicylate drug (more than 100 years old) and has demonstrated anti-inflammatory, analgesic, antipyretic, and antirheumatic activities, it is also used to inhibit platelet aggregation, thus reducing cardiac mortality, and the therapeutic utility of aspirin continues to increase. "PDR Generics " (PDR Generics, 1996, second edition, Medical Economics, Montvale, New Jersey, pg 243) has listed many medical uses of aspirin. Unfortunately, a number of side effects are associated with the use of salicylates, most notably GI disturbances such as dyspepsia, heartburn, vomiting, gastroduodenal bleeding, gastric ulcerations, and gastritis . Gastroduodenal bleeding induced by salicylates is generally painless but can lead to fecal blood loss and may cause a persistent iron deficiency anemia. In a crossover study, uncoated aspirin at a dosage of 325 mg tablets given three times a day caused an average fecal blood loss of 4.33 ml per day (PDR Generics, 1996, second edition, Medical Economics, Montvale, New Jersey, pg 242). Coated aspirin at the same dosage caused an average fecal blood loss of 1.5 ml per day. Aspirin and its esters have a very low solubility in water and may stay in the GI tract for a long time and can cause gastric mucosal cell damage. Aspirin and its esters are also very hydrophobic, and when they enter the cell membrane (hydrophobic layer), they will stay there as part of the membrane due to their similarity. Due to these reasons, the absorption rate of aspirin is very slow. It takes 2 hours for uncoated aspirin tablets to reach the peak salicylate level and much longer for coated aspirin tablets.
Technical Solution
This invention relates to the preparation of novel positively charged pro-drugs of acetylsalicylic acid or its analogues and their use medicinally. These pro-drugs have the general formula(l) "Structure 1".
Structure 1
In which, R^ represents CH , C^H, H , or other lower alkyl groups; R2 represents H, one of any alkyl, alkyloxy, or alkenyl residues having 1 to 6 carbon atoms, or aryl residues; R represents H, one of any alkyl, alkyloxy, or alkenyl residues having 1 to 6 carbon atoms, or aryl residues; R represents H, one of any alkyl, alkyloxy, or alkenyl 4 residues having 1 to 6 carbon atoms, or aryl residues; X represents O, S or NH; A' represents Cl , Br , F, I , AcO , acetylsalicylate, citrate, salicylate, or any negative ions; and n=G, 1,2,3,4,5......
In an embodiment of the present invention, there is provided a method of treating an aspirin-treatable condition in a human or animal in need thereof comprising administering a compound having a general formula of Structure 1:
Structure 1 wherein:
Ri is selected from the group consisting of CH3, C2H5, and C3H7; R2 is H, R3 is selected from the group consisting of H or C1-6 alkyl; R4 is selected from the group consisting of H or C 1.6 alkyl; X represents 0, S, or NH; A' represents a negative ion; and n is 1, 2, 3, 4, or 5; or a pharmaceutical composition comprising a compound having a general formula of Structure i; wherein the compound or pharmaceutical composition is administered transdermally to any part of the body to deliver a therapeutically effective plasma level of the compound.
In another embodiment of the present invention, there is provided use of a compound having a general formula of Structure 1:
Structure 1 wherein:
Ri is selected from the group consisting of CH3, C2H5, and C3H7; R2 is H, R3 is selected from the group consisting of H or Ci.6 alkyl; R4 is selected from the group consisting of H or C1-6 alkyl; X represents O, S, or NH; A' represents a negative ion; and n is 1, 2, 3, 4, or 5; in the manufacture of a medicament for the treatment of an aspirin-treatable condition in a human or animal, wherein the medicament is administered transdermally to any part of the body to deliver a therapeutically effective plasma level of the compound.
In yet another embodiment of the present invention, there is provided a transdermal therapeutic application system comprising a compound having a general formula of Structure 1:
Structure 1 wherein:
Ri is selected from the group consisting of CH3, C2H5, and C3H7; R2 is H, R-3 is selected from the group consisting of H or C 1.6 alkyl; R4 is selected from the group consisting of H or Ci-6 alkyl; X represents O, S, or NH; A' represents a negative ion; and n is 1, 2, 3, 4, or 5; or a pharmaceutical composition comprising a compound having a general formula of Structure (1)1; wherein the transdermal therapeutic application system further comprises a bandage or a patch comprising an active ingredient containing matrix layer and an impermeable backing layer.
Drug absorption, whether from the gastrointestinal tract or other sites, requires the passage of the drug in a molecular form across the barrier membrane. The drug must first dissolve, and if the drug possesses the desirable biopharmaceutical properties, it will pass from a region of high concentration to a region of low concentration across the membrane into the blood or general circulation. All biological membranes contain lipids as major constituents. The molecules that play the dominant roles in membrane formation all have phosphate-containing highly polar head groups, and, in most cases, two highly hydrophobic hydrocarbon tails. Membranes are bilayers, with the hydrophilic head groups facing outward into the aqueous regions on either side. Very hydrophilic drugs can not pass the hydrophobic layer of membrane and very hydrophobic drugs will stay in the hydrophobic layer as part of the membrane due to their similarities and cannot enter the cytosol on the inside efficiently.
The goal of this invention is to avoid the side effects of aspirin by increasing the solubility of acetylsalieyiic acid in gastric juice and the penetration rate of aspirin through the membrane and skin barrier which will make it administrable transdermally (topical application). These novel pro-drugs of acetylsalieyiic acid have two structural features in common; they have a lipophilic portion and a primary, secondary, or tertiary amine group that exists in the protonated form (hydrophilic part) at physiologic pH. Such a hydrophilic-lipophilic balance is required for efficient passage through the membrane barrier [Susan Milosovich, et a!., J. Pharai. Sci., 82,227(1993)]. The positively charged amino groups largely increase the solubility of the drugs. The sol-utilities of diethylaminoethyl acetylsalicylate. AcGH and acetyisaiicylic acid in pH 7 phosphate buffer were >300 mg and 0.01 mg/ml. In many instances, the slowest or rate-limiting step in the sequence is the dissolution of the drug. Aspirin has a very low solubility in gastric juice. It stays in the GI tract for a long time and may cause gastric mucosal cell damage. When these new pro-drugs are administered orally in a dosage form such as a tablet, capsule, solution, or suspension, they will dissolve in the gastric juice immediately. The positive charge on the amino groups of these pro-drugs will bond to the negative charge on the phosphate head group of membrane. Thus, the local concentration of the outside of the membrane will be very high and will facilitate the passage of these pro-drugs from a region of high concentration to a region of low concentration. When these pro-drugs enter the membrane, the hydrophilic part will push the pro-drug into the cytosol, a semi-liquid concentrated aqueous solution or suspension. Due to the short stay in GI tract, the pro-drugs will not cause gastric mucosal cell damage.
The penetration rates of diethylaminoethyl acetylsalicylate.AcOH, ethyl acetyl-salicylate, and acetylsalicylic acid through human skin were measured in vitro by using modified Franz cells, which were isolated from human skin tissue (360-400 pm thick) of the anterior and posterior thigh areas. The receiving fluid consisted of 10 ml of 2% bovine serum albumin in normal saline and was stirred at 600 rpm. The cumulative amounts of acetylsalicylic acid, ethyl acetylsalicylate, and diethylaminoethyl acetylsalicylate.AcOH penetrating the skin versus time were determined by a specific high-performance liquid chromatography method. The results using a donor consisting of either a 20% suspension of acetylsalicylic acid and ethyl acetylsalicylate or 20% solution of diethylaminoethyl acetylsalicylate.AcOH in 2mL of pH 7.4 phosphate buffer (0.2M) are shown in Figure 1. Apparent flux values of 0.25 mg, 1 mg, and 100 mg/cm /h were calculated for acetylsalicylic acid, ethyl acetylsalicylate (the no positive charged normal ester of acetylsalicylic acid), and diethylaminoethyl acetylsalicylate .AcOH . The results suggest that the pro-drug, diethylaminoethyl acetylsalicylate.AcOH, diffuses through human skin ~400 times faster than does acetylsalicylic acid itself and ~100 times faster than does ethyl acetylsalicylate. The normal ester, ethyl acetylsalicylate and acetylsalicylic acid itself have very similar penetration rate (only 4 times difference). The results suggest that the positive charge on the di-alkyaminoethyl group has a very important role in the passage of the drug across the membrane and skin barrier. Other pro-drugs of the general "Structure 1" have very high penetration rates and are very close to that of diethylaminoethyl acetylsalicylate.AcOH.
The in vivo rates of penetration of acetylsalicylic acid and diethylaminoethyl acetylsalicylate.AcOH through the skin of intact hairless mice were compared. The donor consisted of either a 30% suspension of acetylsalicyclic acid or a 30% solution of di-ethylaminoethyl acetylsalicylate.AcOH in 1 mL of isopropanol applied to a 1 cm area on the backs of the hairless mice. Plasma levels of salicylic acid (acetylsalicyclic acid has a very short half-live, ~15 minutes in plasma, so the amount of it is difficult to be determined) were determined by a specific high-performance liquid chromatography method. The results (Figure 2) show that the peak levels of salicylic acid were reached ~20 minutes after application of the donor systems. It takes 2 hours for uncoated aspirin tablets to reach the peak salicylate level and much longer for coated aspirin tablets when they are taken orally. The peaks were ~0.01mg/ml for salicylic acid and ~10 mg/ml for diethylaminoethyl acetylsalicylate.AcOH (approximately 100 times difference). ~10mg/ml of salicylic acid in plasma is more than 33-67 times higher than the salicylate plasma level (0.15-0.3 mg/ml) for effective analgesia and 33-50 times higher than the salicylate plasma level (0.2-0.3 mg/ml) for effective anti-inflammatory activity. This is a very exciting result. It will be very easy and fast to deliver therapeutically effective plasma levels of aspirin into the host by these pro-drugs. These results suggest that the pro-drugs can be administered not only orally, but also transdermally for any kind of medical treatments. The in vivo rates of penetration of other prodrugs of the general "Structure 1" are close to that of diethylaminoethyl acetylsalicylate.AcOH .
To check the gastroduodenal bleeding caused by drugs, the rats (two groups, each group had 10 rats) were orally administered with 100 mg/kg of aspirin or diethylaminoethyl acetylsalicylate.AcOH per day for 21 days. We found an average of 5 mg of fecal blood per gram of feces in the aspirin group and none in diethylaminoethyl acetylsalicylate.AcOH group.
The acute toxicity of the pro-drugs were investigated. The LD ^ orally in rats are: 2.3 g/kg and 2.2 g for diethylaminoethyl acetylsalicylate.AcOH and dimethy-laminoethyl acetylsalicylate AcOH . The results show that the pro-drugs are less toxic than aspirin (LD_o=1.5g/kg).
Acetylsalicylic acid has demonstrated anti-inflammatory, analgesic, antipyretic, and antirheumatic activity, inhibits platelet aggregation, reduces cardiac mortality , but salicylic acid has only analgesic and antipyretic activity. A good pro-drug should go back to the drug itself in plasma. Diethylaminoethyl acetylsalicylate .AcOH has two ester function groups. One (acetyl) is from acetylsalicylic acid itself, and the one is the diethylaminoethyl ester (the added one). Both ester groups can be rapidly cleaved by the enzymes in human plasma in vitro. If the acetate group losses faster than diethylaminoethyl, the pro-durg will be changed to diethylaminoethyl salicylate, then to salicylic acid instead of acetylsalicylic acid. Diethylaminoethyl acetylsalicylate.AcOH and Acetylsalicylic acid have very short half-lives (~4 min. and 15 min.) in whole human blood. To determine how much the pro-drugs of acetylsalicylic acid were changed back to the drug itself or diethylaminoethyl salicylate, we diluted whole human blood 20 times with a pH 7.4 phosphate buffer (0.2M). The cumulative amounts of diethylaminoethyl salicylate, acetylsalicylic acid, and salicylic acid were determined by a specific high-performance liquid chromatography method. The results shown the rate of diethylaminoethyl salicylate vs acetylsalicylic acid is 1 vs 4. This means that 80% of the pro-drug was changed back to the drug itself. Due to the pro-drug having a much better absorption rate, the pro-drug will have more strength than the acetylsalicylic acid itself at the same dosage.
The analgetic, antipyretic, and anti-inflammatory activities of diethylaminoethyl acetylsalicylate.AcOH were tested using aspirin as a comparison. Other compounds of of the general "Structure 1 " were tested by the same methods and have very similar results as that of diethylaminoethyl acetylsalicylate.AcOH .
Analgetic activity: The prolongation time of pain the threshold of a mouse tail was determined in accordance with the D'Amour-Smith Method (J. Pharmacol. Exp. Ther., 72, 74(1941)). After 200mg/kg of aspirin was administered orally and 200mg/kg of diethylaminoethyl salicylate.AcOH was administered orally and transdermally, the tails of mice were exposed to heat and the prolongation time of pain threshold was determined. The results obtained are shown in Figure 3. In Figure 3, the groups administered 200 mg/kg of diethylaminoethyl salicylate.AcOH orally (C) and transdermally (D) were shown to exhibit stronger analgetic activity than the group administered 200mg/kg of aspirin.
The number of writhings that occurred when mice were administered an acetic acid solution intraperitoneally were counted, and the rate of inhibition based on the control group was calculated. 42 mice were divided into 7 groups (6 mice each). Aspirin (ASA, 50 mg/kg and 100 g) was administered to groups B1 and B2 of mice and diethylaminoethyl acetylsalicylate.AcOH (DEAE-ASA, 50 mg and 100 mg/kg) was administered orally to groups Cl and C2. Diethylaminoethyl acetylsalicylate.AcOH (DEAE-ASA, 50 mg and 100 mg/kg) was administered transdermally to groups Dland D2. The A group is the control group. The test compounds were administered to the mice 30 minutes before the acetic acid solution was administered. The results are shown in following Table 1.
Table 1. The rate of writhings inhibition by and aspirin and its pro-drugs
The results show that diethylaminoethyl acetylsalicylate.AcOH demonstrates better analgetic activity than aspirin. Other compounds of the general "Structure 1" show similar analgetic activity.
Antipyretic activity: Rats received a sterilized E. coli suspension as a pyrogen. 56 rats were divided into 7 groups. The control group is group A. 2 hours later, Aspirin (ASA, B1 for lOOmg/kg and B2 for 150mg/kg) and diethylaminoethyl acetylsalicylate.AcOH (DEAE-ASA, Cl for lOOmg/kg and C2 for 150 mg) were administered orally and diethylaminoethyl acetylsalicylate.AcOH (DEAE-ASA, D1 for 100 mg and D2 for 150 mg/kg) were administered transdermally. The body temperature of rats was taken at 90 min. intervals before and after the administration of the test compounds. The results are shown in the following Table 2.
Table 2. Antipyretic activity of aspirin and its pro-drugs
The results shown that diethylaminoethyl acetylsalicylate.AcOH demonstrated antipyretic activity at 100 mg/kg dose and some better than aspirin. The results show that transdermal administration of diethylaminoethyl acetylsalicylate.AcOH is better than oral administration. Other compounds of the general "Structure 1" show similar antipyretic activity.
Anti-inflammatory activity: 50 mg/kg of diethylaminoethyl acetylsalicylate.AcOH was administered orally or transdermally to rats and 50 mg/kg of aspirin was administered orally. 60 minutes later, a carrageenin solution was administered subcutaneously to the foot pads of the rats. The volume of the hind paw was measured at every hour after the administration of the carrageenin, and the rate of increase in the volume of the paw was calculated and designated as the rate of swelling(%). The results obtained are shown in Figure 4.
The results show that diethylaminoethyl acetylsalicylate.AcOH demonstrated better Anti-inflammatory activity than that of aspirin at 50mg/kg for oral administration and transdermal administration. Other compounds of the general "Structure 1" shown similar anti-inflammatory activity.
It is also known that a high dose of oral acetylsalicylic acid shows an anti-reactive-antiasthmatic activity by inhibition of the cyclooxygenase activity (Bianco, Sebastiano, U.S. Pat. No. 5,570,559), Due to their very high membrane penetration rate, these pro-drugs can be used in treating asthma by spraying into the mouth or nose of a host. They can also be used to treat acne due to their anti-inflammatory properties. They can be used for the treatment and prevention of endothelia dysfunction as well.
The compounds of the general formula(l) "Structure 1" indicated above can be prepared from ASA or its analogues, or from functional derivatives of ASA or its analogues. For example, acid halides or mixed anhydrides of the general formula(2) "Structure 2".
Structure 2
In which represents CH , C^H^, H , or other lower alkyl groups; Y represents halogen, alkoxycarbonyl or substituted aryloxycarbonyloxy, by reaction with compounds of the general formula (3) "Structure 3".
Structure 3
In which, represents H, one of any alkyl, alkyloxy, or alkenyl residues having 1 to 6 carbon atoms, or aryl residues; R2 represents H, one of any alkyl, alkyloxy, or alkenyl residues having 1 to 6 carbon atoms, or aryl residues; X represents O, S or NH; and n=0,l,2,3,4,5.....
The compounds of the general "Structure 1" indicated above can be prepared from ASA or its analogues, by reaction with compounds of the general formula (3) "Structure 3" by using coupling reagents, such as N,N'-Dicyclohexylcarbodiimide , N,N'-Diisopropylcarbodiimide, 0-(Benzotriazol-1 -yl)-N,N,N',N'-tetramethyluroniuTn tetrafluoroborate, 0-(Benzotriazol-1 -yl)-N,N,N',N'-tetramethyluromum hexafluoro phosphate, Benzotriazol-l-yl-oxy-tris(dimethylammo)phosphonium hexafluo-rophosphate, et al.
When X represents O, the compounds of the general formula(l) "Structure 1" indicated above can be prepared from metal salts or organic base salts of acetyl-salicylic acid or its analogues, by reaction with compounds of the general formula (4) "Structure 4".
Structure 4
In which, represents H, one of any alkyl, alkyloxy, or alkenyl residues having 1 to 6 carbon atoms, or aryl residues; represents H, one of any alkyl, alkyloxy, or alkenyl residues having 1 to 6 carbon atoms, or aryl residues; R4 represents H, one of any alkyl, alkyloxy, or alkenyl residues having 1 to 6 carbon atoms, or aryl residues; Z represents halogen, or p-toluenesulphonyl, A' represents Cl’, Br, F, Γ, AcO, acetyl- salicylate, citrate, salicylate, or any negative ions; and n=0,l,2,3,4,5.....
When X represents O, the compounds of the general "Structure 1" indicated above can be prepared from immobilized base salts of acetylsalicylic acid or its analogues of the general formula (5) "Structure 5".
Structure 5
In which, R represents cross-linked resin; R represents CH, C^, CH, or other lower alkyl group; B represents any base groups, such as pyridine, piperidine, tri-ethylamine, or other base groups, by reaction with compounds of the general formula(4) "Structure 4" .
The present invention relates to pharmaceutical preparations comprising pro-drugs of acetylsahcyhc acid and its analogues of the general formula(l) "Structure 1" in addition to customary auxiliaries and excipients, e.g. in the form of tablets, capsules or solutions for administration orally and in the form of solutions, lotion, ointment, emulsion or gel for transdermal administration transdermally. The new active compounds of the general "Structure 1" can be combined with vitamins such as A,B,C or E or beta-carotene, or other pharmaceuticals, such as folic acid, et. al for treating any aspirin-treatable conditions in humans or animals .
Transdermal therapeutic application systems of compounds of the general "Structure 1" or a composition comprising at least one compound of the general formula(l) "Structure 1", as an active ingredient, for treating any aspirin-treatable conditions in humans or animals, especially for preventing thrombosis and other cardiovascular diseases, and cancer prophylaxis can be developed. These systems can be a bandage or a patch comprising one active substance-containing matrix layer and an impermeable backing layer. The most preferable system is an active substance reservoir, which has a permeable bottom facing the skin. By controlling the rate of release, this system enables aspirin to reach constantly optimal therapeutic blood levels to increase effectiveness and reduce the side effects of aspirin. These systems can be worn on wrist, ankle, arm, leg, or any part of body.
Advantageous Effects
These pro-drugs of aspirin have a lipophilic portion and a hydrophilic portion (the amine groups that exist in the protonated form at physiologic pH). The positively charged amino groups of these pro-drugs have two major advantages. The first, it largely increases the solubility of the drugs; when these new pro-drugs are administered orally in a dosage form such as a tablet, capsule, solution, or suspension, they will dissolve in gastric juice immediately. The second, the positive charge on the amino group of these pro-drugs will bond to the negative charge on the phosphate head group of membrane. Thus, the local concentration outside of the membrane will be very high and will facilitate the passage of these pro-drugs from a region of high concentration to a region of low concentration. When these pro-drugs enter the membrane, the hydrophilic part will push the pro-drugs into the cytosol, a semiliquid concentrated aqueous solution or suspension. Due to the short stay in the GI tract, the pro-drugs will not cause gastric mucosal cell damage. Experiment results show that 80% of the prodrug was changed back to the drug itself. The pro-drugs have a much better absorption rate, and thus the pro-drugs will have better strength than the acetylsalicylic acid itself at the same dosage.
The experiment results suggest that the pro-drug, diethylaminoethyl acetyl-salicylate. AcOH, diffuses through human skin -400 times faster than acetylsalicylic acid itself and -100 times faster than ethyl acetylsalicylate. The in vivo rates of penetration of diethylaminoethyl acetylsalicylate. AcOH through the skin of intact hairless mice was very high. It takes 2 hours for uncoated aspirin tablets to reach the peak salicylate plasma level and much longer for coated aspirin tablets when they are taken orally, but diethylaminoethyl acetylsalicylate .AcOH only took about 20 minutes to reach the peak salicylate plasma level. The most exciting result is that the pro-drugs can be administered not only orally, but also transdermally for any type of medical treatment and should avoid most of the side effects of aspirin, most notably GI disturbances such as dyspepsia, gastroduodenal bleeding, gastric ulcerations, and gastritis.
Description of Drawings
Figure 1: Cumulative amounts of acetylsalicylic acid (ASA), ethyl acetyl-salicylate(E-ASA), and diethylaminoethyl acetylsalicylate.AcOH(DEAE-ASA) crossing isolated human skin tissue in Franz cells (n=5). ASA and E-ASA were applied as 20% suspensions. DEAE-ASA was applied as a 20% solution. In each case, the vehicle was pH 7.4 phosphate buffer (0.2 M).
Figure 2: Total plasma levels of salicylic acid (SA) after topical application of 300 mg of acetylsalicylic acid (ASA) or diethylaminoethyl acetylsalicylate.AcOH (DEAE-ASA) to the backs of hairless mice (n=5).
Figure 3. The prolongation time of the pain threshold of the mice tails after 200mg/kg of aspirin (B) was administered orally, 200mg/kg of diethylaminoethyl salicylate.AcOH was administered orally (C) and transdermally (D). A is the control line.
Figure 4. The rate of swelling (%) after a carrageenin injection. 1 hour before the carrageenin injection, 100 mg/kg of spirin was administered orally (B), 100 mg/kg of diethylaminoethyl salicylate.AcOH (C) was administered orally and transdermally (D). A is the control line.
Structure 1. In which, R represents CH , C^H , C H , or other lower alkyl groups; R2 represents H, one of any alkyl, alkyloxy, or alkenyl residues having 1 to 6 carbon atoms, or aryl residues; R^ represents H, one of any alkyl, alkyloxy, or alkenyl residues having 1 to 6 carbon atoms, or aryl residues; R represents H, one of any alkyl, 4 alkyloxy, or alkenyl residues having 1 to 6 carbon atoms, or aryl residues; X represents O, S or NH; A' represents Cl", Br", F, Γ, AcO", acetylsalicylate, citrate, salicylate, or any negative ions; and n=0,l,2,3,4,5......
Best Mode
Preparation of diethylaminoethyl acetylsalicylate.AcOH 18 g (0.1 mol) of o-acetylsalicylic was dissolved in 180 ml of chloroform. 12.5 g of Sodium bicarbonate (0.15 mol) was added into the solution. Water (20 ml) was added with stirring. After the mixture had been stirred for 30 minutes, anhydrous sodium sulfate (200 g) was added. 39g (0.15 mol) of diethylaminoethyl bromide.HBr was added into the mixture and the mixture was stirred for 5 hours at RT. 8.2 g (0.1 mol) of sodium acetate was added into the reaction mixture with stirring. The mixture is stirred for 2 hours. The solid was removed by filtration and washed with chloroform (3 x 50 ml). The solution is concentrated in vacuo to 100 ml. Then 300 ml of hexane was added into the solution. The solid product was collected by filtration and washed with hexane ( 3 x 100 ml). After drying, it yielded 31 g of the desired product (91%). Hygroscopic product; Solubility in water: 300 mg/ml; Elementary analysis: C H NO ; MW: 339.38. Calculated % C: 60.07; H: 7.44; N: 4.15; O: 28.22 ; Found % C: 60.16; H: 7.42; N: 4.13; O: 28.29.1H-NMR(400 MHz, CDCL ): delta: 1.55(t, 6H), 2.08(s, 3H), 2.20(s, 3H), 3.28(m, 4H); 3.70(m,2H), 4.68(m, 2H), 6.5(b, 1H), 7.17(m, 1H), 7.19(m, lH),7.45(m, lH),7.94(m, 1H).
Mode for Invention
Preparation of dimethylaminoethyl acetylsalicylate.AcOH 19.9 g (0.1 mol) of o-acetoxybenzoyl chloride was dissolved in 100 ml of chloroform. The mixture was cooled to 0°C. 15 ml of triethylamine and 8.9 g of dimethylaminoethanol were added into the reaction mixture. The mixture is stirred for 3 hours at RT. 6 g of acetic acid is added into the reaction mixture with stirring. The so lid side product was removed by filtration and washed with chloroform ( 3 x 30 ml). The organic solution was evaporated off. After drying, it yielded 29 g of the desired product (93%). Hygroscopic product; Solubility in water: 350 mg/ml; Elementary analysis: C H NO ; MW: 311.33. Calculated % C: 57.87; H: 6.80; N: 4.50; O: 30.83 ; Found % C: 57.82; H: 6.85; N: 4.48; O: 30.85. H-NMR (400 MHz, CDCL ): delta: 2.09 (s, 3H) 2.21 (s, 3H), 2.90 (s, 6H); 3.71(m,2H), 4.69 (m, 2H), 6.9 (b, 1H), 7.18 (m, 1H), 7.20 (m,lH),7.47(m,lH),7.93 (m, 1H)
Preparation of S-dimethylaminoethyl acetylthiosalicylate.AcOH 19.9 g (0.1 mol) of o-acetoxybenzoyl chloride was dissolved in 100 ml of chloroform. The mixture was cooled to 0°C. 15 ml of triethylamine and 9.3 g of dimethylaminoethyl mercaptan were added into the reaction mixture. The mixture was stirred for 3 hours at RT. 6 g of acetic acid was added into the reaction mixture with stirring. The solid side product was removed by filtration and washed with chloroform ( 3 x 30 ml). The organic solution was evaporated off. After drying, it yielded 28 g of the desired product (87%). Hygroscopic product; Solubility in water: 320 mg/ml; Elementary analysis: C^H^NO^S; MW: 327.4. Calculated % C: 55.03; H: 6.47; N: 4.28; O: 24.43 S:9.79 ; Found % C: 55.02; H: 6.45; N: 4.35; O: 24.49; 9.69. Ή-NMR (400 MHz, CDCL ): delta: 2.09 (s, 3H) 2.21 (s, 3H), 2.90 (s, 6H); 3.31 (t,2H), 3.91 (m, 2H), 6.9 (b, 1H), 7.26 (m, 1H), 7.28 (m,lH),7.55 (m,lH),7.94 (m, 1H)
Preparation of N-dimetiiylaminoethyl acetylsalicylamide.AcOH 19.9 g (0.1 mol) of o-acetoxybenzoyl chloride was dissolved in 100 ml of chloroform. The mixture was cooled to 0°C. 15 ml of triethylamine and 8.9 g of dimethylaminoethylamine were added into the reaction mixture. The mixture was stirred for 3 hours at RT. 6 g of acetic acid was added into the reaction mixture with stirring. The solid side product was removed by filtration and washed with chloroform ( 3 x 30 ml). The organic solution was evaporated off. After drying, yielded 28 g of the desired product(90.2%). Hygroscopic product; Solubility in water: 350 mg/ml; Elementary analysis: C Η N O ; MW: 310.35. Calculated % C: 58.05; H: 7.15; N: 9.03; O: 25.78 ; Found % C: 58.02; H: 7.18; N: 8.98; O: 25.83. ’H-NMR (400 MHz, CDCL ): delta: 2.09 (s, 3H) 2.21 (s, 3H), 2.90 (s, 6H); 3.54 (m,2H), 3.64 (t, 2H), 6.9 (b, 1H), 7.8 (b, 1H); 7.25 (m, 1H), 7.26 (m,lH),7.48 (m,lH), 7.92 (m, 1H) .
Preparation of S-diethylaminoethyl propionylthiosalicylate.AcOH 18 g (0.1 mol) of o-acetylsalicylic acid was dissolved in 100 ml of dichloromethane (DCM). The mixture was cooled to 0°C. 20.6 g of 1,3-Dicyclohexylcarbodiimid was added into the reaction mixture. The mixture was stirred for 30 minutes at 0°C. 14.8 g (0.1 mol) of diethylaminopropyl mercaptan was added into the reaction mixture. The mixture was stirred for 3 h at RT. 6 g of acetic acid was added into the reaction mixture with stirring. The solid side product was removed by filtration and washed with chloroform (3 x 50 ml). The organic solution was evaporated off. After drying, it yielded 32 g of the desired product (86.6%). Hygroscopic product; Solubility in water: 280 mg/ml; Elementary analysis: C H NO S; MW: 369.48. Calculated % C: 58.51; H: 7.37; N: 3.79; 0:21.65 ;S:8.68 Found % C: 58.53; H: 7.39; N: 3.75; O: 21.68; S: 8.65. 'H-NMR (400 MHz, CDCL ): delta: 1.09(t, 3H),1.56 (t, 6H), 2.21 (s, 3H),2.27 (m, 2H) 3.28 (m, 4H), 3.31 (m, 2H); 3.91 (m,2H), 6.8 (b, 1H), 7.25 (m, 1H), 7.26 (m,lH), 7.48 (m,lH), 7.92 (m, 1H)
Preparation of N-diethylaminopropyl acetylsalicylamide.AcOH 18 g (0.1 mol) of o-acetylsalicylic acid was dissolved in 100 ml of acetonitrile. 32.1 g of 0-(Benzotriazol-l-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate and 30 ml of triethylamine were added into the reaction mixture. 13.1 g of dimethylamino-propylamine was added into the reaction mixture. The mixture was stirred for 3 hours at RT. The solvents were evaporated off. 250 ml of ethyl acetate was added into the reaction mixture and the mixture was washed with water (3 x 100 ml). The organic solution was dried over anhydrous sodium sulfate. Sodium sulfate was removed by filtration. 6 g of acetic acid was added into the reaction mixture with stirring. Hexane (200 ml) was added. The solid product was collected by filtration . After drying, it yielded 32 g of the desired product(90.8%).Hygroscopic product; Solubility in water: 280 mg/ml; Elementary analysis: C Η N O ; MW: 352.43. Calculated % C: 61.34; H: I n /.X /. ^ 8.01; N: 7.95; 0:22.70 ; Found % C: 61.25; H: 8.05; N: 7.96; O: 22.74. 'H-NMR (400 MHz, CDCL ): delta: 1.56 (t, 6H) 2.03 (m, 2H) 2.09 (s, 3H), 2.21(s, 3H), 3.24 (m, 2H), 3.20 (m, 2H); 3.24 (m,2H), 6.9 (b, 1H), 7.8 (b, 1H); 7.25 (m, 1H), 7.26 (m,lH),7.48 (m,lH),7.92 (m, 1H).
Preparation of dipropylaminoethyl acetylsalicylate.AcOH 20.3 g (0.1 mol) of sodium o-acetylsalicylate was suspended in 180 ml of chloroform. 28.8 g (0.1 mol) of dipropylaminoethyl bromide.HBr was added into the mixture and the mixture was stirred for 5 hours at RT. 8.2 g (0.1 mol) of sodium acetate was added into the reaction mixture with stirring. The mixture is stirred for 2 hours. The solid was removed by filtration and washed with chloroform (3 x 50 ml). The solution is concentrated in vacuo to 100 ml. Then 300 ml of hexane was added into the solution. The solid product was collected by filtration and washed with hexane ( 3 x 100 ml). After drying, it yielded 30 g of the desired product (81.6%). Hygroscopic product; Solubility in water: 300 mg/ml; Elementary analysis: C^H^NO^; MW: 367.44. Calculated % C: 62.11; H: 7.96; N: 3.81; O: 26.13 ; Found % C: 62.07; H: 7.99; N: 3.78; O: 26.17. 'H-NMR (400 MHz, CDCL ): delta: 0.97 (t, 6H),1.77 (m, 4H), 2.20 (s, 3H), 3.25 (m, 4H); 3.70 (m,2H), 4.69 (m, 2H), 6.8 (b, 1H), 7.17 (m, 1H), 7.19 (m,lH),7.45 (m,lH),7.94 (m, 1H).
Preparation of dipropylaminoethyl acetylsalicylate.AcOH 60 g of Polymer-bound triethylamine (3 mmol/g, 100-200 mesh) was suspended in 180 ml of chloroform. 18 g (0.1 mol) of o-acetylsalicylic acid was added into the mixture with stirring. 43 g (0.15 mol) of dipropylaminoethyl bromide.HBr was added into the mixture and the mixture was stirred for 5 hours at RT. The polymer is removed by filtration and washed with tetrahydrofuran ( 3 x 50 ml). 8.2 g (0.1 mol) of sodium acetate was added into the reaction mixture with stirring. The mixture is stirred for 2 h. The solid was removed by filtration and washed with chloroform (3 x 50 ml). The solution is concentrated in vacuo to 100 ml. Then 300 ml of hexane was added into the solution. The solid product was collected by filtration and washed with hexane ( 3 x 100 ml). After drying, it yielded 31 g of the desired product (91%). Hygroscopic product; Solubility in water: 300 mg/ml; Elementary analysis: C H^NO^; MW: 339.38. Calculated % C: 60.07; H: 7.44; N: 4.15; O: 28.22 ; Found % C: 60.16; H: 7.42; N: 4.13; O: 28.29. Ή-NMR (400 MHz, CDCL ): delta: 1.55 (t, 6H), 2.08 (s, 3H), 2.20 (s, 3H), 3.28 (m, 4H); 3.70 (m,2H), 4.68 (m, 2H), 6.5 (b, 1H), 7.17 (m, 1H), 7.19 (m,lH),7.45 (m,lH),7.94 (m, 1H).
Industrial Applicability
The pro-drugs of of the general "Structure 1" are superior to aspirin. They may be used medicinally in treating any aspirin-treatable conditions in humans or animals. They may be used in the long-term palliative treatment of mild to moderate pain and inflammation of arthritis and other inflammatory conditions. They may be used alone or as an adjunct in the treatment of Kawasald syndrome, thromboembolism after surgery, and unstable angina. They can be used to decrease stool volume and increase weight in acute childhood gastroenteritis, as an adjunct to prevent aortocoronary-artery -bypass graft occlusion, and to prevent thromboembolic complications in chronic artrial fibrillation. They can be used as an adjunct in carotid endarterectomy to reduce platelet aggregation and thromboxane suppression, and they may be prescribed to reduce the development of cataracts, to prevent recurrence of stenosis after coronary angioplasty, and to improve cognitive performance and cerebral blood flow in patients with multi-infract dementia. They may be used as an adjunct to lower plasma glucose in diabetes mellitus and diabeties-induced complications, including diabetic retinopathy, necrobiotic ulcers, and diabetic proteinuria, and to decrease total and cardiovascular mortality. They can be prescribed to reduce the incidence of hemodialysis shunt thrombosis, to decrease the deterioration of renal function and occurrence of end-stage renal disease in patients with type-1 membranoproliferative glomerulonephritis, and to slow the progression of peripheral occlussive arterial disease. They may be used in the prevention of colon cancer and rectal cancer, and arterial embolic complications in patients' prosthetic heart valves. They can also be prescribed to lower the incidence of pregnancy-induced hypertension and preeclamptic toxemia in high-risk women. It is also known that high dose of oral acetylsalicylic acid shows an an-tireactive activity by the inhibition of the cyclooxygenase activity (Bianco, Sebastiano, U.S. Pat. No. 5,570,559). Due to their very high membrane penetration rate, these prodrugs can be used in treating asthma by inhalation to a host. They can be used to treat acne due to their anti-inflammatory properties. They can be used for the treatment and prevention of endothelial dysfunction.
Claims (20)
- diethylaminoethyl acetylsalicylate.
- HA; diethylaminoethyl acetylthiosalicylate.HA; diethylaminoethyl acetylsalicylamide.HA; diethylaminopropyl acetylsalicylamide.HA; dipropylaminoethyl acetylsalicylate.HA; dimethylaminoethyl acetylsalicylate.HA; S-dimethylaminoethyl acetylthiosalicylate.HA; N-dimethylaminoethyl acetylsalicylamide.HA; S-diethylaminoethyl propionylthiosalicylate.HA; and N-diethylaminopropyl acetylsalicylamide.HA; wherein A represents a negative ion.
- 3. The method of claim 1 or 2, wherein the compound is selected from: diethylaminoethyl acetylsalicylate. HA dimethylaminoethyl acetylsalicylate.HA; S-dimethylaminoethyl acetylthiosalicylate.HA; N-dimethylaminoethyl acetylsalicylamide .HA; S-diethylaminoethyl propionylthiosalicylate.HA; N-diethylaminopropyl acetylsalicylamide.HA; and dipropylaminoethyl acetylsalicylate.HA; wherein A represents a negative ion.
- 4. The method of any one of claims 1 to 3, wherein A is Cl , Br , F , I , AcO , acetylsalicylate, oxalate, citrate, or salicylate.
- 5. The method of any one of claims 1 to 4, wherein the pharmaceutical composition is in the form of a solution, lotion, ointment, emulsion, or gel.
- 6. The method of any one of claims 1 to 5, wherein the aspirin-treatable condition is selected from pain from a toothache, pain from a headache, pain from arthritis, other inflammatory pain, fever, preeclampsia, heart attacks, Kawasaki syndrome, thromboembolism after surgery, unstable angina, acute childhood gastroenteritis, aortocoronary-artery-bypass graft occlusion, thromboembolic complications in chronic artrial fibrillation, cataracts, platelet aggregation and thromboxane suppression, recurrence of stenosis after coronary angioplasty, diabetes mellitus and diabetic-induced complications, diabetic retinopathy, necrobiotic ulcers, diabetic proteinuria, an incidence of hemodialysis shunt thrombosis, deterioration of renal function and occurrence of end-stage renal disease in patients with type-1 membranoproliferative glomerulonephritis, progression of peripheral occlusive arterial disease, prevention of colon cancer and rectal cancer, arterial embolic complications in patients prosthetic heart valves, and acne.
- 7. The method of any one of claims 1 to 6, wherein the aspirin-treatable condition is acne or a skin disorder.
- 8. Use of a compound having a general formula of Structure 1:Structure 1 wherein: Ri is selected from the group consisting of CH3, C2H5, and C3H7; R2 is H, R3 is selected from the group consisting of H or C16 alkyl; R4 is selected from the group consisting of H or C16 alkyl; X represents 0, S, or NH; A represents a negative ion; and n is 1, 2, 3, 4, or 5; in the manufacture of a medicament for the treatment of an aspirin-treatable condition in a human or animal, wherein the medicament is administered transdermally to any part of the body to deliver a therapeutically effective plasma level of the compound.
- 9. The use of claim 8, wherein the compound is selected from: diethylaminoethyl acetylsalicylate. HA; diethylaminoethyl acetylthiosalicylate.HA; diethylaminoethyl acetylsalicylamide.HA; diethylaminopropyl acetylsalicylamide.HA; dipropylaminoethyl acetylsalicylate.HA; dimethylaminoethyl acetylsalicylate.HA; S-dimethylaminoethyl acetylthiosalicylate.HA; N-dimethylaminoethyl acetylsalicylamide.HA; S-diethylaminoethyl propionylthiosalicylate.HA; and N-diethylaminopropyl acetylsalicylamide.HA; wherein A represents a negative ion.
- 10. The use of claim 8 or 9, wherein the compound is selected from: diethylaminoethyl acetylsalicylate. HA dimethylaminoethyl acetylsalicylate.HA; S-dimethylaminoethyl acetylthiosalicylate.HA; N-dimethylaminoethyl acetylsalicylamide .HA; S-diethylaminoethyl propionylthiosalicylate.HA; N-diethylaminopropyl acetylsalicylamide.HA; and dipropylaminoethyl acetylsalicylate.HA; wherein A represents a negative ion.
- 11. The use of any one of claims 8 to 10, wherein A is Cl , Br , F , I , AcO , acetylsalicylate, oxalate, citrate, or salicylate.
- 12. The use of any one of claims 8 to 11, wherein the aspirin-treatable condition is selected from pain from a toothache, pain from a headache, pain from arthritis, other inflammatory pain, fever, preeclampsia, heart attacks, Kawasaki syndrome, thromboembolism after surgery, unstable angina, acute childhood gastroenteritis, aortocoronary-artery-bypass graft occlusion, thromboembolic complications in chronic artrial fibrillation, cataracts, platelet aggregation and thromboxane suppression, recurrence of stenosis after coronary angioplasty, diabetes mellitus and diabetic-induced complications, diabetic retinopathy, necrobiotic ulcers, diabetic proteinuria, an incidence of hemodialysis shunt thrombosis, deterioration of renal function and occurrence of end-stage renal disease in patients with type-1 membranoproliferative glomerulonephritis, progression of peripheral occlusive arterial disease, prevention of colon cancer and rectal cancer, arterial embolic complications in patients prosthetic heart valves, and acne.
- 13. The use of any one of claims 8 to 12, wherein the aspirin-treatable condition is acne or a skin disorder.
- 14. A transdermal therapeutic application system comprising a compound having a general formula of Structure 1:Structure 1 wherein: Ri is selected from the group consisting of CH3, C2H5, and C3H7; R2 is H, R3 is selected from the group consisting of H or C| () alkyl; R4 is selected from the group consisting of H or C16 alkyl; X represents O, S, or NH; A represents a negative ion; and n is 1, 2, 3, 4, or 5; or a pharmaceutical composition comprising a compound having a general formula of Structure l; wherein the transdermal therapeutic application system further comprises a bandage or a patch comprising an active ingredient containing matrix layer and an impermeable backing layer.
- 15. The transdermal therapeutic application system of claim 14, wherein the compound is selected from: diethylaminoethyl acetylsalicylate. HA; diethylaminoethyl acetylthiosalicylate.HA; diethylaminoethyl acetylsalicylamide.HA; diethylaminopropyl acetylsalicylamide.HA; dipropylaminoethyl acetylsalicylate.HA; dimethylaminoethyl acetylsalicylate.HA; S-dimethylaminoethyl acetylthiosalicylate.HA; N-dimethylaminoethyl acetylsalicylamide .HA; S-diethylaminoethyl propionylthiosalicylate.HA; and N-diethylaminopropyl acetylsalicylamide.HA; wherein A represents a negative ion.
- 16. The transdermal therapeutic application system of claim 14 or 15, wherein the compound is selected from: diethylaminoethyl acetylsalicylate. HA dimethylaminoethyl acetylsalicylate.HA; S-dimethylaminoethyl acetylthiosalicylate.HA; N-dimethylaminoethyl acetylsalicylamide.HA; S-diethylaminoethyl propionylthiosalicylate.HA; N-diethylaminopropyl acetylsalicylamide.HA; and dipropylaminoethyl acetylsalicylate.HA; wherein A represents a negative ion.
- 17. The transdermal therapeutic application system of any one of claims 14 to 16, wherein A is Cl , Br , F , I , AcO , acetylsalicylate, oxalate, citrate, or salicylate.
- 18. The transdermal therapeutic application system of any one of claims 14 to 17, further comprising an active ingredient reservoir, which comprises a permeable bottom facing the skin, and by controlling the rate of release, the system enables constant optimal therapeutic blood level of aspirin in a subject the system is applied to.
- 19. A method of treating or preventing an aspirin-treatable condition in a human or animal in need thereof comprising administering a transdermal therapeutic application system of any one of claims 14 to 18.
- 20. The method of claim 19, wherein the aspirin-treatable condition is thrombosis, other cardiovascular diseases, or cancer prophylaxis.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013206215A AU2013206215C9 (en) | 2006-07-09 | 2013-06-07 | Positively charged water-soluble prodrugs of aspirin |
| AU2016219617A AU2016219617B2 (en) | 2006-07-09 | 2016-08-24 | Positively charged water-soluble prodrugs of aspirin |
| AU2018217329A AU2018217329A1 (en) | 2006-07-09 | 2018-08-17 | Positively charged water-soluble prodrugs of aspirin |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2006/052318 WO2008007171A1 (en) | 2006-07-09 | 2006-07-09 | Positively charged water-soluble prodrugs of aspirin |
| AU2006346195 | 2006-07-09 | ||
| AU2006346195A AU2006346195B2 (en) | 2006-07-09 | 2006-07-09 | Positively charged water-soluble prodrugs of aspirin |
| AU2013206215A AU2013206215C9 (en) | 2006-07-09 | 2013-06-07 | Positively charged water-soluble prodrugs of aspirin |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006346195A Division AU2006346195B2 (en) | 2006-07-09 | 2006-07-09 | Positively charged water-soluble prodrugs of aspirin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016219617A Division AU2016219617B2 (en) | 2006-07-09 | 2016-08-24 | Positively charged water-soluble prodrugs of aspirin |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| AU2013206215A1 AU2013206215A1 (en) | 2013-06-27 |
| AU2013206215B2 AU2013206215B2 (en) | 2016-06-02 |
| AU2013206215C1 true AU2013206215C1 (en) | 2016-12-22 |
| AU2013206215C9 AU2013206215C9 (en) | 2018-03-08 |
Family
ID=48671031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013206215A Ceased AU2013206215C9 (en) | 2006-07-09 | 2013-06-07 | Positively charged water-soluble prodrugs of aspirin |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2013206215C9 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160168108A1 (en) | 2014-12-16 | 2016-06-16 | Adt Pharmaceuticals, Inc. | Method of treating or preventing ras-mediated diseases |
| US9862698B2 (en) | 2014-12-16 | 2018-01-09 | Adt Pharmaceuticals, Inc. | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
| JP7169008B2 (en) | 2018-04-26 | 2022-11-10 | エーディーティー ファーマシューティカルズ，エルエルシー | Anti-Cancer Indene, Indane, Azaindene, Azaindane, Pharmaceutical Compositions and Uses |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH399486A (en) * | 1962-10-02 | 1965-09-30 | Biosedra Lab | Process for the preparation of new salicylamides |
| EP0152379A3 (en) * | 1984-02-15 | 1986-10-29 | Ciba-Geigy Ag | Process for preparing pharmaceutical compositions containing unilamellar liposomes |
-
2013
- 2013-06-07 AU AU2013206215A patent/AU2013206215C9/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013206215A1 (en) | 2013-06-27 |
| AU2013206215B2 (en) | 2016-06-02 |
| AU2013206215C9 (en) | 2018-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006346195B2 (en) | Positively charged water-soluble prodrugs of aspirin | |
| CA2658712C (en) | Positively charged water-soluble prodrugs of diclofenac with very fast skin penetration rate | |
| CA2657636C (en) | Positively charged water soluble prodrugs of ibuprofen with very fast skin penetration rate | |
| EP2623495B1 (en) | Positively charged water-soluble prodrugs of n-arylanthranilic acids with very fast skin penetration rate | |
| WO2008012603A1 (en) | Positively charged water-soluble prodrugs of diflunisal and related compounds with very fast skin penetration rate | |
| AU2016219617B2 (en) | Positively charged water-soluble prodrugs of aspirin | |
| AU2013206215C1 (en) | Positively charged water-soluble prodrugs of aspirin | |
| JP5905411B2 (en) | Positively charged water-soluble prodrug of aspirin | |
| AU2013231152B2 (en) | Positively charged water-soluble pro-drugs of ibuprofen | |
| JP6588485B2 (en) | Positively charged water-soluble prodrug of aspirin | |
| WO2008012605A1 (en) | Positively charged water-soluble prodrugs of ketoprofen and related compounds with very fast skin penetration rate | |
| JP6289438B2 (en) | Positively charged water-soluble prodrug of aspirin | |
| HK1187037A (en) | Positively charged water-soluble prodrugs of aspirin | |
| JP2018058899A (en) | Positively charged water-soluble prodrug of aspirin | |
| AU2018202140A1 (en) | Positively charged water-soluble pro-drugs of ibuprofen | |
| HK1237331A (en) | Positively charged water-soluble prodrugs of ibuprofen with very fast skin penetration rate | |
| HK1237331A1 (en) | Positively charged water-soluble prodrugs of ibuprofen with very fast skin penetration rate | |
| HK1188210A (en) | Positively charged water-soluble prodrugs of n-arylanthranilic acids with very fast skin penetration rate | |
| HK1199724A1 (en) | Positively charged water-soluble prodrugs of aspirin | |
| HK1198001A (en) | Positively charged water-soluble prodrugs of diclofenac with very fast skin penetration rate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 SEP 2016 Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 SEP 2016 . |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 SEP 2016 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| SREP | Specification republished | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |